Radheshyam N

Radheshyam N

India

Publications
  • Research Article
    KDR gene as a Predictive Biomarker of Response to Regorafenib in Patients with Metastatic Colorectal Cancer (mCRC)
    Author(s): Srinivasa BJ, Lalkota Bhanu Prakash, Nasiruddin M and Radheshyam N Srinivasa BJ, Lalkota Bhanu Prakash, Nasiruddin M and Radheshyam N

    Background: Regorafenib is an oral diphenyl urea multikinase inhibitor which is anti- angiogenic, and has shown promising anti-tumor activity in Metastatic Colorectal Cancer (mCRC). Reports have shown that response to regorafenib is more favourable in patients with KDR gene mutation. This study correlates KDR gene mutation as an ideal predictive biomarker to regorafenib (Tyrosine Kinase Inhibitor) response in metastatic colorectal cancer (MCRC). Methods: This is a single centre prospective analysis of total 9 patients at HCG cancer speciality centre, Bengaluru, India. The median age of 9 patients was 54 years (21-71 years). 5 patients were male and 4 patients were female, 6 patients are African and 3 were Indian. KRAS gene was found to be mutated in 6 patients and wild type in 3 patients. Out of 9 patients, 6 have received FOLFOX-4 chemother.. View More»
    DOI: 10.4172/2153-0645.1000173

    Abstract PDF